183 related articles for article (PubMed ID: 36750899)
41. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
42. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
Yin K; Li YS; Zheng MM; Jiang BY; Li WF; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Yang XN; Chen HJ; Yan HH; Li LL; Wu YL; Zhang XC
Lung Cancer; 2019 May; 131():134-138. PubMed ID: 31027690
[TBL] [Abstract][Full Text] [Related]
43. Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
Takamori S; Toyokawa G; Okamoto I; Takada K; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Mukae N; Hirai F; Tagawa T; Oda Y; Iwaki T; Iihara K; Nakanishi Y; Maehara Y
Anticancer Res; 2018 Jan; 38(1):553-557. PubMed ID: 29277823
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T
Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424
[No Abstract] [Full Text] [Related]
45. Applicability of graded prognostic assessment of lung cancer using molecular markers to lung adenocarcinoma patients with brain metastases.
Li H; Lian J; Han S; Wang W; Jia H; Cao J; Zhang X; Song X; Jia S; Ren J; Yang W; Xi Y; Lan S
Oncotarget; 2017 Sep; 8(41):70727-70735. PubMed ID: 29050314
[TBL] [Abstract][Full Text] [Related]
46. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
[TBL] [Abstract][Full Text] [Related]
47. Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases.
Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G
ESMO Open; 2023 Dec; 8(6):102069. PubMed ID: 37988952
[TBL] [Abstract][Full Text] [Related]
48. Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases.
Guo S; Reddy CA; Chao ST; Suh JH; Barnett GH; Vogelbaum MA; Videtic GM
Lung Cancer; 2012 Aug; 77(2):389-93. PubMed ID: 22542706
[TBL] [Abstract][Full Text] [Related]
49. Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
Ouyang W; Yu J; Zhou Y; Hu J; Huang Z; Zhang J; Xie C
BMC Cancer; 2020 Jul; 20(1):699. PubMed ID: 32723319
[TBL] [Abstract][Full Text] [Related]
50. The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan.
Cheng WC; Shen YC; Chien CR; Liao WC; Chen CH; Hsia TC; Tu CY; Chen HJ
Thorac Cancer; 2022 May; 13(10):1505-1512. PubMed ID: 35394114
[TBL] [Abstract][Full Text] [Related]
51. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
[TBL] [Abstract][Full Text] [Related]
52. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.
Luo D; Ye X; Hu Z; Peng K; Song Y; Yin X; Zhu G; Ji Q; Peng Y
Tumour Biol; 2014 Mar; 35(3):2437-44. PubMed ID: 24197981
[TBL] [Abstract][Full Text] [Related]
53. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
54. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
55. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
[TBL] [Abstract][Full Text] [Related]
56. Management of Non-Small-Cell Lung Cancer Patients Initially Diagnosed With 1 to 3 Synchronous Brain-Only Metastases: A Retrospective Study.
Chen XR; Hou X; Li DL; Sai K; Dinglin XX; Chen J; Wang N; Li MC; Wang KC; Chen LK
Clin Lung Cancer; 2021 Jan; 22(1):e25-e34. PubMed ID: 32839132
[TBL] [Abstract][Full Text] [Related]
57. Establishment of a prognostic risk prediction modelfor non-small cell lung cancer patients with brainmetastases: a retrospective study.
Hou F; Hou Y; Sun XD; Lv J; Jiang HM; Zhang M; Liu C; Deng ZY
PeerJ; 2023; 11():e15678. PubMed ID: 37456882
[TBL] [Abstract][Full Text] [Related]
58. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
[TBL] [Abstract][Full Text] [Related]
59. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
60. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer.
Kaul D; Angelidis A; Budach V; Ghadjar P; Kufeld M; Badakhshi H
Radiat Oncol; 2015 Nov; 10():244. PubMed ID: 26611493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
